Sarah Cannon Research Institute
Lesleigh Averitt has a diverse work experience spanning over a decade. Currently, they are working at the Sarah Cannon Research Institute as the Director of Site Support Operations, a role they have held since June 2023. Prior to this, they served as the Director of Regulatory Affairs from January 2023 to June 2023. In addition, they were the Senior Manager of Site Relationships and Support Services from November 2022 to January 2023.
Before joining the Sarah Cannon Research Institute, Lesleigh worked at Sarah Cannon starting in 2015. During their tenure there, they held multiple roles, including Senior Manager of Site Relationships and Support Services from December 2020 to November 2022. Lesleigh also worked as a Manager of Data Operations from July 2018 to December 2020, a Senior Study Coordinator from April 2018 to July 2018, a Study Coordinator from May 2016 to April 2018, and a Data Coordinator from May 2015 to May 2016.
Lesleigh's career began at Freds Pharmacy, where they worked as a Certified Pharmacy Technician from July 2010 to June 2015.
Lesleigh Averitt, MBA, obtained their Bachelor of Science (B.S.) degree in Chemistry from Austin Peay State University. Lesleigh attended the university from 2009 to 2014. Later, they pursued a Healthcare MBA from Belmont University's Jack C. Massey College of Business, specializing in the field of healthcare. Their MBA program at Belmont University spanned from 2018 to 2020.
This person is not in any teams
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.